Editas Medicine Overview
Editas Medicine Target Price
See Editas Medicine's analyst price targets ($4) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$3.07
Average Target Price
$4.00
30.3% upside
30.3% upside1 analysts in the last 4 months
High: $4 | Low: $4
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-05 | Chardan Capital | $4 | 30.3% upside |  |
| 2026-03-09 | Robert W. Baird | $6 | 95.4% upside | |
| 2024-11-05 | BarclaysGena Wang | $5 | 62.9% upside | |
| 2024-10-23 | Wells FargoYanan Zhu | $9 | 193.2% upside | |
| 2024-10-22 | Robert W. BairdJoel Beatty | $10 | 225.7% upside | |
| 2024-08-08 | Truist FinancialJoon Lee | $12 | 290.9% upside | |
| 2024-08-08 | Bank of America SecuritiesGreg Harrison | $15 | 388.6% upside | |
| 2024-05-30 | Evercore ISILiisa Bayko | $7 | 128% upside | |
| 2024-05-09 | Morgan StanleyMatthew Harrison | $7 | 128% upside | |
| 2023-09-28 | Stifel NicolausDae Gon Ha | $17 | 453.7% upside | |
| 2022-12-13 | Citigroup | $11 | 258.3% upside | |
| 2022-11-18 | Morgan Stanley | $8 | 160.6% upside | |
| 2022-11-18 | RBC Capital | $14 | 356% upside | |
| 2022-11-18 | Truist FinancialJoon Lee | $35 | 1040.1% upside | |
| 2022-11-18 | Oppenheimer | $12 | 290.9% upside | |
| 2022-11-18 | Credit Suisse | $13 | 323.5% upside | |
| 2022-11-18 | Chardan Capital | $35 | 1040.1% upside | |
| 2022-01-06 | Morgan StanleyMatthew Harrison | $24 | 681.8% upside | |
| 2021-11-08 | Robert W. BairdJoel Beatty | $44 | 1333.2% upside | |
| 2021-09-29 | Truist FinancialJoon Lee | $80 | 2505.9% upside | |